A Phase I Study of ABT-888 in Combination With Topotecan Plus Carboplatin for High-Risk Myeloproliferative Disorders and AML Out of Myeloproliferative Disorders

Trial Profile

A Phase I Study of ABT-888 in Combination With Topotecan Plus Carboplatin for High-Risk Myeloproliferative Disorders and AML Out of Myeloproliferative Disorders

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Veliparib (Primary) ; Carboplatin; Topotecan
  • Indications Acute myeloid leukaemia; Haematological malignancies; Leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders; Polycythaemia vera; Thrombocytosis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Jul 2017 Results (n=95) assessing exposure-response analysis to inform the planning of a phase II trial published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 18 Mar 2017 Results assessing exposure-response analysis to inform the planning of a phase II trial, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 22 Aug 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top